158018-53-2

Usage

Uses

Used in Pharmaceutical Industry:
4-EPIANHYDROCHLORTETRACYCLINE HYDROCHLORIDE, CAN BE USED AS SECONDARY STANDARD is used as a reference compound for ensuring the quality and stability of tetracycline-based drugs. Its role as a secondary standard helps in the accurate assessment of drug potency and degradation, ensuring the safety and efficacy of tetracycline medications.
Used in Quality Control and Research:
In the fields of quality control and research, 4-EPIANHYDROCHLORTETRACYCLINE HYDROCHLORIDE, CAN BE USED AS SECONDARY STANDARD is utilized as a benchmark for the development and validation of analytical methods and techniques. Its use in these areas contributes to the advancement of tetracycline-related drug development and the improvement of existing pharmaceutical formulations.

InChI:InChI=1/C22H21ClN2O7/c1-7-8-6-9-16(25(2)3)18(28)15(21(24)31)20(30)22(9,32)19(29)13(8)17(27)14-11(26)5-4-10(23)12(7)14/h4-5,9,16,26-27,31-32H,6,24H2,1-3H3/p+1/t9-,16+,22-/m0/s1

Upstream product

• 64-72-2 chlortetracycline hydrochloride 

Relevant academic research and scientific papers

Semisynthetic analogues of anhydrotetracycline as inhibitors of tetracycline destructase enzymes

The synthesis and biological evaluation of semisynthetic anhydrotetracycline analogues as small molecule inhibitors of tetracycline-inactivating enzymes are reported. Inhibitor potency was found to vary as a function of enzyme (major) and substrate-inhibitor pair (minor), and anhydrotetracycline analogue stability to enzymatic and nonenzymatic degradation in solution contributes to their ability to rescue tetracycline activity in whole cell Escherichia coli expressing tetracycline destructase enzymes. Taken collectively, these results provide the framework for the rational design of next-generation inhibitor libraries en route to a viable and proactive adjuvant approach to combat the enzymatic degradation of tetracycline antibiotics.

INHIBITION AND DIAGNOSTICS OF EMERGING TETRACYCLINE RESISTANCE ENZYMES

The present disclosure provides compositions and methods for treating bacterial infections in a subject. The methods comprise administering a compound that binds a FAD-dependent flavoenzyme and a tetracycline, analog, derivative, or pharmaceutically acceptable salt thereof.